Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lodoxamide tromethamine** is a synthetic mast cell stabilizer used as a topical (ophthalmic) medication to treat ocular allergy conditions such as **vernal keratoconjunctivitis**, **vernal conjunctivitis**, and **vernal keratitis**. It works by inhibiting Type I immediate hypersensitivity reactions. Its mechanism includes preventing the release of histamine and other inflammatory mediators (such as peptidoleukotrienes and eosinophil chemotactic factors) by stabilizing the membrane of mast cells and is believed to prevent calcium influx into mast cells upon antigen stimulation. Lodoxamide tromethamine does not have intrinsic vasoconstrictor, antihistaminic, cyclooxygenase inhibitor, or other anti-inflammatory activity. The drug is supplied as a 0.1% ophthalmic solution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lodoxamide tromethamine.